1. Home
  2. AVDL vs PRTA Comparison

AVDL vs PRTA Comparison

Compare AVDL & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVDL
  • PRTA
  • Stock Information
  • Founded
  • AVDL 2015
  • PRTA 2012
  • Country
  • AVDL Ireland
  • PRTA Ireland
  • Employees
  • AVDL N/A
  • PRTA N/A
  • Industry
  • AVDL Biotechnology: Pharmaceutical Preparations
  • PRTA Biotechnology: Pharmaceutical Preparations
  • Sector
  • AVDL Health Care
  • PRTA Health Care
  • Exchange
  • AVDL Nasdaq
  • PRTA Nasdaq
  • Market Cap
  • AVDL 784.6M
  • PRTA 809.8M
  • IPO Year
  • AVDL 1996
  • PRTA N/A
  • Fundamental
  • Price
  • AVDL $8.03
  • PRTA $9.20
  • Analyst Decision
  • AVDL Strong Buy
  • PRTA Buy
  • Analyst Count
  • AVDL 7
  • PRTA 9
  • Target Price
  • AVDL $18.86
  • PRTA $54.57
  • AVG Volume (30 Days)
  • AVDL 1.1M
  • PRTA 572.3K
  • Earning Date
  • AVDL 05-07-2025
  • PRTA 05-07-2025
  • Dividend Yield
  • AVDL N/A
  • PRTA N/A
  • EPS Growth
  • AVDL N/A
  • PRTA N/A
  • EPS
  • AVDL N/A
  • PRTA N/A
  • Revenue
  • AVDL $169,117,000.00
  • PRTA $135,157,000.00
  • Revenue This Year
  • AVDL $50.53
  • PRTA N/A
  • Revenue Next Year
  • AVDL $32.33
  • PRTA $131.71
  • P/E Ratio
  • AVDL N/A
  • PRTA N/A
  • Revenue Growth
  • AVDL 504.79
  • PRTA 47.92
  • 52 Week Low
  • AVDL $6.38
  • PRTA $9.10
  • 52 Week High
  • AVDL $19.09
  • PRTA $25.42
  • Technical
  • Relative Strength Index (RSI)
  • AVDL 54.47
  • PRTA 26.58
  • Support Level
  • AVDL $6.38
  • PRTA $9.30
  • Resistance Level
  • AVDL $8.22
  • PRTA $10.45
  • Average True Range (ATR)
  • AVDL 0.48
  • PRTA 0.81
  • MACD
  • AVDL 0.11
  • PRTA -0.15
  • Stochastic Oscillator
  • AVDL 89.67
  • PRTA 2.77

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Share on Social Networks: